

## Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline

<b>Guideline Name</b>	Akynzeo (netupitant/palonosetron)
-----------------------	-----------------------------------

### 1. Criteria

<b>Product Name: Akynzeo</b>	
Approval Length	24 Month(s)
Guideline Type	Prior Authorization
<p><b>Approval Criteria</b></p> <p>1 - Akynzeo is being requested for the prevention of nausea and vomiting associated with cancer chemotherapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is 18 years of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is receiving moderately to highly emetogenic intravenous chemotherapy as defined by NCCN Clinical Practice Guidelines for Antiemesis</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Akynzeo will be taken with dexamethasone</p>	

### 2. Background

<b>Benefit/Coverage/Program Information</b>
<p><b>RATIONALE</b> Promote clinically appropriate utilization of Akynzeo based on its FDA approved indication and dosing.</p> <p><b>FDA APPROVED INDICATIONS</b> AKYNZEO is a fixed combination of netupitant, a substance P/neurokinin 1 (NK<sub>1</sub>) receptor antagonist, and palonosetron, a serotonin-3 (5-HT<sub>3</sub>) and neurokinin 1 (NK<sub>1</sub>) receptor antagonist indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Oral palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.</p>

**REFERENCES**

- Eisai Inc. Akynzeo prescribing information. Helsinn Therapeutics Inc. Iselin, NJ. April 2018.
- NCCN Clinical Practice Guidelines in Oncology, Antiemesis Version 1.2019.

Created: 09/16
P&T Approval: 12/02/19
Effective: 1/1/20